Semaglutida: noticia sobre un ensayo presentada en un congreso médico que explora cómo la terapia influyó en la calidad de vida de pacientes.
Key Takeaways
- Trial reported a 24% reduction in major renal events versus placebo
- Health-utility scores favored treatment by +0.021, about eight extra healthy days yearly
- Four of five EQ-5D domains improved significantly; anxiety and depression showed no benefit